Authors: JAILLON P DUPUIS B DAHAN R BOTTINEAU G CARON J CAZOR JL CHAUVENET M CLEMENT JP ESCANDE D FAISANDIER Y FUNCKBRENTANO C KOLSKY H KOEN R LACROIX D LEENHARDT A LEHNER JP PROST JF SWYNGHEDAUW B VASSORT G WEISSENBURGER J WOHLHUTER C

Citation: P. Jaillon et al., DRUG-INDUCED TORSADE-DE-POINTES - PRECLIN ICAL AND CLINICAL-STUDIES FOR THE PREDICTION OF A POTENTIAL PROARRHYTHMIC ADVERSE DRUG REACTION, Therapie, 52(4), 1997, pp. 271-280

Authors: DUBOIS B STEHLE B LEHNER JP DEROUESNE C BOURIN M LAMOUR Y BLIN O JOURDAIN G ALPEROVITCH A ALLARD M BILLARDON M CATTELIN F CHILDS M DELACOURTE M DELALLEAU B DIGIAMBERARDINO L EMRE M GENTHON R GONI S JAFFARD R LACOMBLEZ L LEBERT F LEGER JM MAHIEUX F MICHEL B PARTIOT A PASQUIER F PAUL HPS PUECH A REIGNEAU O RENAULT S SCHLENCK A

Citation: B. Dubois et al., METHODOLOGY FOR DEVELOPING DRUGS IN ALZHE IMER-DISEASE, Therapie, 51(4), 1996, pp. 444-448

Authors: BOURIN M ALLAIN H ATASSI G BLANCHARD JC BLIN O BOST PE BRAQUET P CHAUMETRIFFAUD D DANGUMAU J ELIA AF HOUDEBINE LM LECHAT P LECOMTE JM LEFUR G LEHNER JP MARSAC J PETIT P SASSARD J SYROTA A VILAINE JP

Citation: M. Bourin et al., THE FUTURE OF PHARMACOLOGICAL MODELS, Therapie, 50(4), 1995, pp. 375-379

Authors: DAHAN R JAILLON P LEHNER JP CAZOR JL CLOARECBLANCHARD L DAHAN R DUCHIER J GUINOT P JAILLON P LEHNER JP LOEB F MACQUINMAVIER C PUECH A ROLAND E ROUVEIX B TEULEESPIE M THULLIEZ C VITOU P

Citation: R. Dahan et al., HOW TO PREDICT THE THERAPEUTIC DOSE RANGE TO BE TESTED IN PHASE-III CLINICAL-TRIALS, Therapie, 48(4), 1993, pp. 297-301

Authors: ASSAYAG P CHAILLEY O LEHNER JP BROCHET E DEMANGE J REZVANI Y GUEROT C VALERE PE

Citation: P. Assayag et al., VOLUNTARY SEQUENTIAL AMBULATORY RECORDING FOR ARRHYTHMIA DETECTION - A MULTICENTER STUDY OF 1287 SYMPTOMATIC PATIENTS, Archives des maladies du coeur et des vaisseaux, 85(3), 1992, pp. 281-286